Retrospective record review on timing of COVID-19 vaccination and cardiac surgery.
COVID-19
SARS-CoV-2
adult cardiac surgery
vaccination
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
revised:
18
07
2022
received:
12
06
2022
accepted:
21
07
2022
pubmed:
3
9
2022
medline:
12
10
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
Novel clinical challenges are faced by cardiac surgeons under the coronavirus disease 2019 (COVID-19) pandemic. Amidst the uncertainties faced due to the socioeconomic and public health impact, there is little evidence surrounding COVID-19 vaccination in patients undergoing cardiac surgery. Timing of vaccination and postvaccination adverse effects are required parameters to discuss with cardiac surgical patients. This is a single-center, retrospective observational study. All patients who underwent adult cardiac surgery at the Prince of Wales Hospital, Hong Kong from January 2021 to December 2021 were included. Postoperative clinical outcomes, COVID-19 vaccination status, and vaccination-related adverse effects were collected. A total of 426 patients; 117 (27%) underwent isolated coronary artery bypass grafting, 111 (26%) underwent valvular surgery, and 97 (23%) underwent aortic surgery. Patients received either Sinovac CoronaVac or Pfizer BNT162b2 vaccine. Overall vaccination rate with at least 1 dose was 52% (n = 212), 15% (n = 63) received the first dose before surgery, 36% (n = 149) received the first dose vaccination after surgery. Rate of completion with second and third doses of vaccination were 22% (n = 89) and 4.9% (n = 20), respectively. The mean timing of first dose of vaccine after surgery was 216 ± 84 days from operation. Three (1.4%) patients recorded vaccination-related complications. COVID-19 vaccination is safe in patients who received major cardiac surgery, with low adverse effects recorded and no vaccine-related mortality observed. A time frame of 3-6 months after cardiac surgery receiving COVID-19 vaccination is reasonable and could serve as a guidance for future COVID-19 vaccination booster programs.
Sections du résumé
BACKGROUND
BACKGROUND
Novel clinical challenges are faced by cardiac surgeons under the coronavirus disease 2019 (COVID-19) pandemic. Amidst the uncertainties faced due to the socioeconomic and public health impact, there is little evidence surrounding COVID-19 vaccination in patients undergoing cardiac surgery. Timing of vaccination and postvaccination adverse effects are required parameters to discuss with cardiac surgical patients.
METHODS
METHODS
This is a single-center, retrospective observational study. All patients who underwent adult cardiac surgery at the Prince of Wales Hospital, Hong Kong from January 2021 to December 2021 were included. Postoperative clinical outcomes, COVID-19 vaccination status, and vaccination-related adverse effects were collected.
RESULTS
RESULTS
A total of 426 patients; 117 (27%) underwent isolated coronary artery bypass grafting, 111 (26%) underwent valvular surgery, and 97 (23%) underwent aortic surgery. Patients received either Sinovac CoronaVac or Pfizer BNT162b2 vaccine. Overall vaccination rate with at least 1 dose was 52% (n = 212), 15% (n = 63) received the first dose before surgery, 36% (n = 149) received the first dose vaccination after surgery. Rate of completion with second and third doses of vaccination were 22% (n = 89) and 4.9% (n = 20), respectively. The mean timing of first dose of vaccine after surgery was 216 ± 84 days from operation. Three (1.4%) patients recorded vaccination-related complications.
CONCLUSIONS
CONCLUSIONS
COVID-19 vaccination is safe in patients who received major cardiac surgery, with low adverse effects recorded and no vaccine-related mortality observed. A time frame of 3-6 months after cardiac surgery receiving COVID-19 vaccination is reasonable and could serve as a guidance for future COVID-19 vaccination booster programs.
Identifiants
pubmed: 36054404
doi: 10.1111/jocs.16883
pmc: PMC9538689
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3634-3638Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Nat Med. 2022 Feb;28(2):410-422
pubmed: 34907393
Ann Thorac Surg. 2021 Nov;112(5):1707-1715
pubmed: 34370980
J Card Surg. 2020 Aug;35(8):1988-2008
pubmed: 32652713
N Engl J Med. 2021 Sep 2;385(10):875-884
pubmed: 34233097
Anaesthesia. 2021 Jun;76(6):748-758
pubmed: 33690889
Drug Discov Ther. 2021;15(3):118-123
pubmed: 34234059
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Card Surg. 2022 Nov;37(11):3634-3638
pubmed: 36054404
Hong Kong Med J. 2021 Apr;27(2):90-91
pubmed: 33879624
Int Arch Occup Environ Health. 2013 Jul;86(5):561-9
pubmed: 22684974
Breast Cancer Res Treat. 2021 Aug;188(3):825-826
pubmed: 34156582
MMWR Morb Mortal Wkly Rep. 2022 Apr 15;71(15):545-548
pubmed: 35421076
JAMA Cardiol. 2021 Oct 1;6(10):1115-1117
pubmed: 34185047
Lancet Microbe. 2021 Jul;2(7):e311-e319
pubmed: 33846704
Rev Med Virol. 2022 Jul;32(4):e2318
pubmed: 34921468
Open Heart. 2016 Jan 13;3(1):e000322
pubmed: 26835141